Fibrate use in the United States and Canada

JAMA

Volumn 306, Issue 2, 2011, Pages 157-

  Tenenbaum, Alexander ^a   Fisman, Enrique Z ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROGENIC DYSLIPIDEMIA; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; HUMAN; LETTER; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG UTILIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; STATISTICS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; DYSLIPIDEMIAS; FENOFIBRATE; FIBRIC ACIDS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 79960158092     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.945     Document Type: Letter

References (4)

1. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA. 2011;305(12):1217-1224.
2. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692-694.
3. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875- 1884.
4. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.